Dysglycaemia in non-diabetic hypertensive patients: Comparison of the impact of two different classifications of impaired fasting glucose on the cardiovascular risk profile

Journal of Human Hypertension

Volumn 23, Issue 5, 2009, Pages 332-338

  Dell'Omo, G ^a   Penno, G ^a   Del Prato, S ^a   Mariani, M ^a   Pedrinelli, R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD GLUCOSE; CHOLESTEROL, HDL; COMORBIDITY; CORONARY DISEASE; FASTING; FEMALE; HUMANS; HYPERTENSION; LEUKOCYTE COUNT; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREDIABETIC STATE; PREVALENCE; REFERENCE VALUES; RISK ASSESSMENT; TRIGLYCERIDES;

EID: 67349221724     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.142     Document Type: Article

References (40)

1. Mancia G. The association of hypertension and diabetes: Prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 2005; 42(Suppl 1): S17-S25.
2. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
3. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912.
4. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969.
5. The Expert Committee on the diagnosis and classification of diabetes mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
6. The Expert Committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
7. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
8. Salmasi AM, Alimo A, Dancy M. Prevalence of unrecognized abnormal glucose tolerance in patients attending a hospital hypertension clinic. Am J Hypertens 2004; 17: 483-488.
9. Korhonen P, Aarnio P, Saaresranta T, Jaatinen P, Kantola I. Glucose homeostasis in hypertensive subjects. Hypertension 2008; 51: 945-949.
10. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: The current status on definition and intervention. Diabet Med 2002; 19: 708-723.
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
12. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
13. Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: The price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinol Metab Clin North Am 2005; 34: 49-62.
14. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001; 161: 361-366.
15. Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Gaziano JM. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006; 47: 45-50.
16. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-2898.
17. McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am J Epidemiol 1990; 131: 443-453.
18. Kim SH, Chunawala L, Linde R, Reaven GM. Comparison of the 1997 and 2003 American Diabetes Association classification of impaired fasting glucose: Impact on prevalence of impaired fasting glucose, coronary heart disease risk factors, and coronary heart disease in a community-based medical practice. J Am Coll Cardiol 2006; 48 293-297.
19. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43: 1817-1822.
20. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia Report of a WHO/IDF Consultation World Health Organization: Geneva, Switzerland, 2006.
21. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Bittner V, Cauley JA et al. Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. Ann Intern Med 2005; 142: 813-820.
22. Rijkelijkhuizen JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Dekker JM. High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: The Hoorn study. Diabetes Care 2007; 30: 332-336.
23. Pankow JS, Kwan DK, Duncan BB, Schmidt MI, Couper DJ, Golden S et al Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: The Atherosclerosis Risk in Communities Study. Diabetes Care 2007; 30: 325-331.
24. Borch-Johnsen K, Colagiuri S, Balkau B, Glümer C, Carstensen B, Ramachandran A et al. Creating a pandemic of prediabetes: The proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 2004; 47: 1396-1402.
25. Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304.
26. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371: 1927-1935.
27. Castelli WP. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol 1992; 70: 3H-9H.
28. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999; 22: 1971-1977.
29. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 1998; 279 1477-1482.
30. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: Insights from mechanistic studies. Lancet 2008; 371: 1800-1809.
31. Vaccaro O, Ruffa G, Imperatore G, Iovino V, Rivellese AA, Riccardi G. Risk of diabetes in the new diagnostic category of impaired fasting glucose: A prospective analysis. Diabetes Care 1999; 22: 1490-1493.
32. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: The San Antonio heart study. Diabetes Care 2003; 26: 3153-3159.
33. Bianchi C, Miccoli R, Penno G, Del Prato S. Primary prevention of cardiovascular disease in people with dysglycemia. Diabetes Care 2008; 31(Suppl 2): S208-S214.
34. Scheen AJ. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes? Diabetes Metab 2007; 33: 3-12.
35. Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR, Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Determinants of new-onset diabetes among 19 257 hypertensive patients randomized in the Anglo-Scandinavian cardiac outcomes trial - blood pressure lowering arm and the relative influence of antihypertensive medication. Diabetes Care 2008; 31: 982-988.
36. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G et al Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.
37. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225-1237.
38. Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R, Nathan DM. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: Results from the Baltimore Longitudinal Study on Aging. Diabetes 2004; 53 2095-2100.
39. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403-414.
40. Bastuji-Garin S, Deverly A, Moyse D, Castaigne A, Mancia G, de Leeuw PW et al. Intervention as a Goal in Hypertension Treatment Study Group: The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens 2002; 20: 1973-1980.